Company Orgenesis Inc OTC Bulletin Board

Equities

US68619K1051

Medical Equipment, Supplies & Distribution

Business description: Orgenesis Inc

Sales by Activity: Orgenesis Inc

Geographical breakdown of sales: Orgenesis Inc

Managers: Orgenesis Inc

Members of the board: Orgenesis Inc

Shareholders: Orgenesis Inc

Company details: Orgenesis Inc

Other Medical Equipment, Supplies & Distribution

Sector

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Dec. 27	Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director	CI
Nov. 13	Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	CI

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâs therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâs services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Fiscal Period: December	2019	2020	2021	2022	2023
Therapies	-	-	-	6.43M	515K
Octomera	-	-	-	35.17M	68K
Corporate and Eliminations	-3.16M	-	-	-	-
Eliminations	-	-	-	-5.58M	-53K
Point-Of-Care Business	3.11M	7.65M	35.5M	-	-
Contract Development and Manufacturing Organization (CDMO)	33.31M	-	-	-	-

See all business segments

Fiscal Period: December	2019	2020	2021	2022	2023
Belgium	33.26M	-	-	-	-

See all geographic segments

Director	Title	Age	Since
Sarah Ferber CTO	Chief Tech/Sci/R&D Officer	71	2012-02-01
Vered Caplan CEO	Chief Executive Officer	56	2013-12-23
Victor Miller DFI	Director of Finance/CFO	55	2024-01-01
Heiko von der Leyen CTO	Chief Tech/Sci/R&D Officer	-	2020-08-31
Gerhard Bauer PRN	Corporate Officer/Principal	-	2023-09-05

See ORGENESIS INC governance

Manager	Title	Age	Since
Vered Caplan CHM	Chairman	56	2014-08-13
Yaron Adler BRD	Director/Board Member	54	2012-04-16
Ashish Nanda BRD	Director/Board Member	59	2017-02-21

Composition of the Board of Directors

Name	Equities	%	Valuation
Jacob Safier 9.886 %	511,010	9.886 %	965 809 $
Vanguard Global Advisers LLC 1.761 %	91,023	1.761 %	172 033 $
Knoll Capital Management LP 1.228 %	63,473	1.228 %	119 964 $
Geode Capital Management LLC 0.7358 %	38,037	0.7358 %	71 890 $
Vered Caplan 0.5382 %	27,819	0.5382 %	52 578 $

List of ORGENESIS INC shareholders

Orgenesis, Inc.

20271 Goldenrod Lane

20876, Germantown

+480 659 6404

http://www.orgenesis.com

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ABBOTT LABORATORIES	+1.68%	+0.49%	-0.79%	-10.83%	193B
MEDTRONIC PLC	+1.14%	+6.98%	-0.29%	-19.72%	110B
BECTON, DICKINSON AND COMPANY	+0.92%	+0.38%	-0.19%	-9.93%	67.45B
CENCORA, INC.	+0.59%	+1.07%	+9.00%	+78.40%	45.94B
HOYA CORPORATION	0.00%	-0.29%	+12.51%	+33.38%	44.9B
DEXCOM, INC.	+5.39%	+9.08%	-31.85%	-21.07%	31.4B
TERUMO CORPORATION	-1.01%	-2.22%	+16.21%	+37.01%	28.03B
WEST PHARMACEUTICAL SERVICES, INC.	+1.10%	+0.14%	-4.12%	-10.73%	23.83B
ZIMMER BIOMET HOLDINGS, INC.	+2.08%	+3.72%	-11.59%	-14.18%	21.2B
Average	+1.32%	+0.77%	-1.23%	+6.92%	62.77B
Weighted average by Cap.	+1.33%	+1.11%	-0.20%	+0.00%

See all sector performances

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Other Medical Equipment, Supplies & Distribution